Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

[1]  R. Palmiter,et al.  Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y , 1996, Nature.

[2]  J. Holst,et al.  The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones , 1996, Diabetes.

[3]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[4]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[5]  D. D’Alessio,et al.  Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. , 1996, The Journal of clinical investigation.

[6]  D. D’Alessio,et al.  Enteral Enhancement of Glucose Disposition by Both Insulin-Dependent and Insulin-Independent Processes: A Physiological Role of Glucagon-Like Peptide I , 1995, Diabetes.

[7]  P. Froguel,et al.  Cloning, Functional Expression, and Chromosomal Localization of the Human Pancreatic Islet Glucose-Dependent Insulinotropic Polypeptide Receptor , 1995, Diabetes.

[8]  B. Göke,et al.  Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. , 1995, Endocrine reviews.

[9]  P. Zabel,et al.  Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM , 1995, Diabetes.

[10]  S. Mojsov,et al.  Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences , 1995, FEBS letters.

[11]  J. Egan,et al.  Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. , 1994, Endocrinology.

[12]  D. Drucker,et al.  Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. , 1994, Endocrinology.

[13]  S. Kahn,et al.  Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. , 1994, The Journal of clinical investigation.

[14]  J. Holst,et al.  Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. , 1994, Metabolism: clinical and experimental.

[15]  Shaoping Deng,et al.  Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor , 1993, Diabetes.

[16]  J. Roder,et al.  Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Wheeler,et al.  Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. , 1993, Endocrinology.

[18]  A. Joyner,et al.  Production of completely ES cell-derived fetuses. , 1993 .

[19]  A. Joyner,et al.  Production of targeted embryonic stem cell clones. , 1993 .

[20]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[21]  D. Drucker,et al.  Alterations in proglucagon processing and inhibition of proglucagon gene expression in transgenic mice which contain a chimeric proglucagon-SV40 T antigen gene. , 1992, The Journal of biological chemistry.

[22]  B. Thorens.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Koob,et al.  Endogenous corticotropin-releasing factor modulates feeding induced by neuropeptide Y or a tail-pinch stressor , 1992, Peptides.

[24]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[25]  R. Bronson,et al.  Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene , 1991, Cell.

[26]  S. Kanse,et al.  Identification and characterization of glucagon‐like peptide‐1 7–36 amide‐binding sites in the rat brain and lung , 1988, FEBS letters.

[27]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[28]  D. Drucker,et al.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Mantyh,et al.  Estrous cyclicity of 125I-cholecystokinin octapeptide binding in the ventromedial hypothalamic nucleus. Evidence for downmodulation by estrogen. , 1987, Neuroendocrinology.

[30]  G. Weir,et al.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.

[31]  J. Holst,et al.  Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.

[32]  N. Hoosein,et al.  Human glucagon‐like peptides 1 and 2 activate rat brain adenylate cyclase , 1984, FEBS letters.